Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER0303 (evaluating NSCLC clinical antitumor efficacy through anlo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Zhong, Hua, Wu, Jun, Chu, Tianqing, Zhang, Lele, Li, Hua, Wang, Qiming, Li, Rong, Zhao, Yizhuo, Gu, Aiqin, Wang, Huimin, Shi, Chunlei, Xiong, Liwen, Zhang, Xueyan, Zhang, Wei, Lou, Yuqing, Yan, Bo, Dong, Yu, Zhang, Yanwei, Li, Baolan, Zhang, Li, Zhao, Xiaodong, Li, Kai, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774020/
https://www.ncbi.nlm.nih.gov/pubmed/31592412
http://dx.doi.org/10.1002/advs.201900721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774020/
https://www.ncbi.nlm.nih.gov/pubmed/31592412
http://dx.doi.org/10.1002/advs.201900721

Ejemplares similares